Changes

October 2025 — reviewed. A literature search was conducted in September 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to recommendations have been made.

Update

Goals

To support healthcare professionals to:

• Recognize the clinical features of Osgood-Schlatter disease.
• Consider other causes of knee pain.
• Manage Osgood-Schlatter disease in primary care.
• Refer to a physiotherapist or orthopaedic specialist as appropriate.

Outcome measures

Audit criteria

QOF indicators

QIPP - Options for local implementation

No QIPP indicators were found during the review of this topic.

NICE quality standards

What is it?

• Osgood-Schlatter disease is a traction apophysitis (inflammation) of the tibial tuberosity, the bony prominence just below the kneecap.
  • It is a common cause of anterior knee pain in adolescents, especially those who participate in sports.
  • The condition is usually unilateral but affects both knees in 20–30% of cases.

[Circi, 2017; Holden, 2020; Ladenhauf, 2020; Corbi, 2022; AAOS, 2024] 

What causes it?

• Osgood-Schlatter disease is thought to result from repetitive traction of the quadriceps on the patellar tendon at its insertion into the proximal tibial apophysis (growth plate/ossification centre), causing small avulsion injuries and inflammation. 
  • The condition typically develops during the adolescent growth spurt, before the tibial tuberosity has completed ossification. The quadriceps strength, particularly in adolescents participating in sports that involve running and jumping, may exceed the ability of the tibial tuberosity to resist that force.
  • Healing and growth of avulsed fragments produce minimal to marked firm enlargement of the tibial tubercle, depending on the severity and frequency of injury.
  • Bony fragments, known as 'ossicles', may occur in people with more severe Osgood-Schlatter disease. They develop from avulsed fragments that fail to reunite properly with the apophysis despite healing.

[Circi, 2017; Patel, 2017; Guldhammer, 2019; Holden, 2020; Ladenhauf, 2020; Corbi, 2022; van Leeuwen, 2022]

How common is it?

• Osgood-Schlatter disease is a common cause of anterior knee pain in adolescents, particularly those who play sports.
  • It affects approximately 1 in 10 adolescents [Cairns, 2018; Rathleff, 2020; Corbi, 2022; Chandra, 2024] and up to 1 in 5 adolescents who participate in sports involving high-impact activities, such as running and jumping [Cairns, 2018].
  • A cross-sectional study (n = 956) of Brazilian adolescents aged 12–15 years found that Osgood–Schlatter disease symptoms were experienced by 9.8% of students (11% of boys and 8.3% of girls) and were more common in those active in sports (13%) compared with those not active (6.7%) [De Lucena, 2011].
  • A retrospective cohort study using electronic health records from over 200,000 general practice patients in and around Rotterdam, Netherlands, found that the mean incidence of Osgood–Schlatter disease among 8–18-year-olds was 3.8 per 1000 person–years, with boys showing a higher incidence (4.9) than girls (2.7) and peak incidence occurring at 12 years in boys and 11 years in girls [van Leeuwen, 2022].

What are the risk factors?

• Risk factors for Osgood-Schlatter disease include [Patel, 2017; Guldhammer, 2019; Ladenhauf, 2020; Corbi, 2022; Chandra, 2024]:
  • Age, typically 12–15 years in boys and 8–13 years in girls.
  • Participation in high-impact sports involving running, jumping, or repetitive knee extension.  
  • Biomechanical risk factors, such as quadriceps muscle tightness and reduced flexibility of the hamstring muscles, particularly shortening of the rectus femoris [Nakase, 2015].
• Male sex has historically been reported as a risk factor. However, more recent studies indicate a narrowing of this gap, with little to no difference in sex distribution, likely reflecting the increased participation of girls in regular, high-impact sports [Ladenhauf, 2020].

What is the prognosis of Osgood-Schlatter disease?

• The symptoms of Osgood–Schlatter disease typically resolve over weeks or months, often coinciding with the end of a growth spurt.
  • Complete recovery is expected when the tibial growth plate closes, usually between 14 and 18 years of age [Gholve, 2007; Weiler, 2011].
  • However, some studies and reviews suggest that recovery may be slower or less complete than generally anticipated: a prospective cohort study (n = 46 adolescents aged 10–14 years) found that 37% of participants still experienced knee pain at a median follow-up of 42 months, which was associated with lower sports-related function and health-related quality of life [Holden, 2021].
• Osgood–Schlatter disease persists into adulthood in about 10% of people [Gholve, 2007; Weiler, 2011] [Rathleff, 2020; Corbi, 2022].
  • Symptoms, including pain on kneeling and knee pain after activity, typically affect those with marked enlargement of the tibial tuberosity and/or ossicle formation in the patellar tendon.
  • Persistent disease has been linked to chronic pain, reduced participation in sports, decreased lower-body strength, and lower quality of life.

How should I assess a person with suspected Osgood-Schlatter disease?

• Ask about the symptoms experienced.
  • Osgood–Schlatter disease typically occurs during adolescence and presents with knee pain and swelling.
  • Pain associated with Osgood–Schlatter disease is:
    
    • Localized to the tibial tuberosity.
    • Gradual in onset, initially mild and intermittent, but may progress to severe, continuous pain that causes a limp.
    • Usually unilateral, though both knees are affected in up to 30% of people.
    • Exacerbated by activities such as running, jumping, or kneeling, and relieved by rest.
• Examine the person.
  • Findings associated with Osgood-Schlatter disease on examination include:
    • Tenderness over the tibial tuberosity.
    • Pain provoked by resisted knee extension.
    • Tightness of the quadriceps and hamstrings.
    • Swelling or bony enlargement of the tibial tuberosity.
    • A normal passive range of movement.
    • The absence of effusion.
• Exclude an alternative cause for knee pain.
  • Clinical features associated with serious alternative diagnoses include trauma, systemic symptoms (such as fever, weight loss, or sweats), bone or joint pain elsewhere, night pain, pain after rest, and referred pain.
• If there are no features suggestive of another cause of knee pain, Osgood-Schlatter disease may be diagnosed clinically.
  • A knee X-ray is not routinely recommended. If undertaken, results may be normal or may demonstrate anterior soft tissue swelling, thickening of the patellar tendon, fragmentation of the tibial tubercle, or ossicle. 
  • Imaging (urgency depending on the clinical situation) may be considered if loose ossicles or alternative diagnoses are suspected. Seek specialist advice if uncertain.

What else might it be?

• Differential diagnoses of Osgood-Schlatter disease include:
  • Traumatic knee injury — likely when knee pain starts suddenly after trauma and is associated with abnormal physical signs. Possible injuries include meniscal injuries, collateral or cruciate ligament injuries, stress fractures of the patella, tibial tuberosity fracture, and prepatellar and infrapatellar bursitis.
  • Inflammatory or systemic joint conditions — such as juvenile idiopathic arthritis, which may affect the knee alone or multiple joints, typically presenting with joint pain, swelling, and morning stiffness. 
  • Referred pain from the hip — including slipped upper femoral epiphysis (more common in adolescents, especially those overweight), transient synovitis (typically in children younger than 10 years), and Perthes’ disease (avascular necrosis of the femoral head epiphysis). For more information, see the CKS topic on Acute childhood limp.
  • Infection — such as septic arthritis or osteomyelitis, typically presenting with acute-onset pain, swelling, warmth, and sometimes systemic features, such as fever or malaise. For more information, see the section on Red flags in the CKS topic on Knee pain – assessment.
  • Bone tumours — rare, usually presenting with severe knee pain that persists at night or at rest, possibly associated with bone or joint pain at other sites, weight loss, or general malaise. For more information, see the CKS topics on Bone and soft tissue sarcoma, Childhood cancers, and Haematological cancers.
  • Other causes — including osteochondritis dissecans, patellofemoral pain syndrome, chondromalacia patellae, and patellar dislocation or subluxation. For more information, see the CKS topic on Acute childhood limp.

Scenario: Management of suspected Osgood-Schlatter disease

From age 6 years onwards.

Search strategy

Scope of search

A literature search was conducted for guidelines, systematic reviews and randomized controlled trials on primary care management of Osgood-Schlatter disease.

Search dates

October 2020 - September 2025

Key search terms

Various combinations of searches were carried out. The terms listed below are the core search terms that were used for Medline.

• Osgood-Schlatter$.tw., osteoarthritis.tw.,overuse injury.tw., tibial apophysitis.tw., anterior knee pain.tw.

Sources of guidelines

• National Institute for Health and Care Excellence (NICE)
• Scottish Intercollegiate Guidelines Network (SIGN)
• Royal College of Physicians
• Royal College of General Practitioners
• Royal College of Nursing
• NICE Evidence
• World Health Organization
• Guidelines International Network
• TRIP database
• Agency for Healthcare Research and Quality
• National Health and Medical Research Council (Australia)
• Royal Australian College of General Practitioners
• British Columbia Medical Association
• Canadian Medical Association
• Alberta Medical Association
• Michigan Quality Improvement Consortium
• Singapore Ministry of Health
• National Resource for Infection Control
• RefHELP NHS Lothian Referral Guidelines
• Medline (with guideline filter)
• Driver and Vehicle Licensing Agency
• NHS Health at Work (occupational health practice)

Sources of systematic reviews and meta-analyses

• The Cochrane Library:
  • Systematic reviews
  • Protocols
  • Database of Abstracts of Reviews of Effects
• Medline (with systematic review filter)
• EMBASE (with systematic review filter)

Sources of health technology assessments and economic appraisals

• NIHR Health Technology Assessment programme
• The Cochrane Library:
  • NHS Economic Evaluations
  • Health Technology Assessments
• Canadian Agency for Drugs and Technologies in Health
• International Network of Agencies for Health Technology Assessment

Sources of randomized controlled trials

• The Cochrane Library:
  • Central Register of Controlled Trials
• Medline (with randomized controlled trial filter)
• EMBASE (with randomized controlled trial filter)

Sources of evidence based reviews and evidence summaries

• Drug and Therapeutics Bulletin
• TRIP database
• Central Services Agency COMPASS Therapeutic Notes

Sources of national policy

• Department of Health
• Health Management Information Consortium (HMIC)

Patient experiences

• Healthtalk
• BMJ - Patient Journeys

Sources of medicines information

The following sources are used by CKS pharmacists and are not necessarily searched by CKS information specialists for all topics. Some of these resources are not freely available and require subscriptions to access content.

• British National Formulary (BNF)
• electronic Medicines Compendium (eMC)
• European Medicines Agency (EMEA)
• Medicines and Healthcare products Regulatory Agency (MHRA)
• REPROTOX
• Scottish Medicines Consortium
• Stockley's Drug Interactions
• TERIS
• TOXBASE
• Micromedex
• UK Medicines Information

Stakeholder engagement

Our policy

The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:

• Clinical accuracy.
• Consistency with other providers of clinical knowledge for primary care.
• Accuracy of implementation of national guidance (in particular NICE guidelines).
• Usability.

Principles of the consultation process

• The process is inclusive and any individual may participate.
• To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.
• Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.
• Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.
• External reviewers are not paid for commenting on the draft topics.
• Discussion with an individual or an organization about the CKS response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).
• All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.
• All reviewers are invited to be acknowledged on the website. All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.

Stakeholders

• Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the Getting involved section of the Clarity Informatics website.
• Stakeholders identified from the following groups are invited to review draft topics:
  • Experts in the topic area.
  • Professional organizations and societies (for example, Royal Colleges).
  • Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.
  • Guideline development groups where the topic is an implementation of a guideline.
  • The British National Formulary team.
  • The editorial team that develop MeReC Publications.
• Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.

Patient engagement

Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:

• Topic selection
• Scoping of topic
• Selection of clinical scenarios
• First draft internal review
• Second draft internal review
• External review
• Final draft and pre-publication

Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.

Evidence exclusion criteria

Our policy

Scoping a literature search, and reviewing the evidence for CKS is a methodical and systematic process that is carried out by the lead clinical author for each topic. Relevant evidence is gathered in order that the clinical author can make fully informed decisions and recommendations. It is important to note that some evidence may be excluded for a variety of reasons. These reasons may be applied across all CKS topics or may be specific to a given topic.

Studies identified during literature searches are reviewed to identify the most appropriate information to author a CKS topic, ensuring any recommendations are based on the best evidence. We use the principles of the GRADE and PICOT approaches to assess the quality of published research. We use the principles of AGREE II to assess the quality of published guidelines.

Standard exclusions for scoping literature:

• Animal studies
• Original research is not written in English

Possible exclusions for reviewed literature:

• Sample size too small or study underpowered
• Bias evident or promotional literature
• Population not relevant
• Intervention/treatment not relevant
• Outcomes not relevant
• Outcomes have no clear evidence of clinical effectiveness
• Setting not relevant
• Not relevant to UK
• Incorrect study type
• Review article
• Duplicate reference

Organizational, behavioural and financial barriers

Our policy

The CKS literature searches take into consideration the following concepts, which are discussed at the initial scoping of the topic.

• Feasibility
  • Studies are selected depending on whether the intervention under investigation is available in the NHS and can be practically and safely undertaken in primary care.
• Organizational and Financial Impact Analysis
• Studies are selected and evaluated on whether the intervention under investigations may have an impact on local clinical service provision or national impact on cost for the NHS. The principles of clinical budget impact analysis are adhered to, evaluated and recorded by the author. The following factors are considered when making this assessment and analysis.
  • Eligible population
  • Current interventions
  • Likely uptake of new intervention or recommendation
  • Cost of the current or new intervention mix
  • Impact on other costs
  • Condition-related costs
  • In-direct costs and service impacts
  • Time dependencies
• Cost-effectiveness or cost-benefit analysis studies are identified where available. 

We also evaluate and include evidence from NICE accredited sources which provide economic evaluations of recommendations, such as NICE guidelines. When a recommended action may not be possible because of resource constraints, this is explicitly indicated to healthcare professionals by the wording of the CKS recommendation.

Declarations of interest

Our policy

Clarity Informatics requests that all those involved in the writing and reviewing of topics, and those involved in the external review process to declare any competing interests. Signed copies are securely held by Clarity Informatics and are available on request with the permission of the individual. A copy of the declaration of interest form which participants are asked to complete annually is also available on request. A brief outline of the declarations of interest policy is described here and full details of the policy is available on the Clarity Informatics website. Declarations of interests of the authors are not routinely published, however competing interests of all those involved in the topic update or development are listed below. Competing interests include:

• Personal financial interests
• Personal family interest
• Personal non-financial interest
• Non-personal financial gain or benefit

Although particular attention is given to interests that could result in financial gains or losses for the individual, competing interests may also arise from academic competition or for political, personal, religious, and reputational reasons. An individual is not obliged to seek out knowledge of work done for, or on behalf of, the healthcare industry within the departments for which they are responsible if they would not normally expect to be informed.

Who should declare competing interests?

Any individual (or organization) involved in developing, reviewing, or commenting on clinical content, particularly the recommendations should declare competing interests. This includes the authoring team members, expert advisers, external reviewers of draft topics, individuals providing feedback on published topics, and Editorial Steering Group members. Declarations of interest are completed annually for authoring team and editorial steering group members, and are completed at the start of the topic update and development process for external stakeholders.

Competing interests declared for this topic:

None.